A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2022
This article has no abstract
Epistemonikos ID: dca21b19c31d9bd1b638143e9a06318551dd1729
First added on: Apr 17, 2025